Insider Selling: Vericel Co. (NASDAQ:VCEL) CEO Sells 17,500 Shares of Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vericel Stock Performance

Shares of Vericel stock opened at $41.66 on Monday. The stock’s fifty day moving average is $45.26 and its 200 day moving average is $46.67. The stock has a market cap of $2.02 billion, a P/E ratio of -4,166.00 and a beta of 1.67. Vericel Co. has a one year low of $32.28 and a one year high of $54.10.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm earned ($0.11) earnings per share. Analysts predict that Vericel Co. will post 0.12 EPS for the current year.

Institutional Investors Weigh In On Vericel

Institutional investors and hedge funds have recently bought and sold shares of the business. UniSuper Management Pty Ltd bought a new stake in Vericel during the first quarter valued at about $595,000. BNP Paribas Financial Markets increased its holdings in shares of Vericel by 99.7% in the first quarter. BNP Paribas Financial Markets now owns 111,760 shares of the biotechnology company’s stock worth $5,814,000 after purchasing an additional 55,796 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Vericel by 10.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock worth $53,149,000 after purchasing an additional 100,797 shares during the last quarter. Silvercrest Asset Management Group LLC bought a new stake in shares of Vericel in the first quarter worth about $6,538,000. Finally, Geneva Capital Management LLC increased its holdings in shares of Vericel by 43.6% in the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock worth $35,330,000 after purchasing an additional 206,202 shares during the last quarter.

Analyst Upgrades and Downgrades

VCEL has been the subject of a number of recent research reports. Canaccord Genuity Group began coverage on Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. HC Wainwright boosted their target price on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group began coverage on shares of Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. Truist Financial boosted their price objective on shares of Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Stephens raised their target price on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.71.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.